At present, the treatment of HER2-positive GC faces some important unresolved problems, including treatment resistance caused by tumor heterogeneity (37), insufficient response rate to targeted therapy (25, 45), lack of back-line treatment strategies, and unclear benefits of immune checkpoint inhibitors for this patient population (46). This evidence concerns the gene ERBB2 and neoplasm.